WMG Financial Advisors’s First Trust NYSE Arca Biotechnology Index Fund FBT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-2,720
Closed -$488K 128
2025
Q3
$488K Sell
2,720
-176
-6% -$30K 0.16% 93
2025
Q2
$467K Sell
2,896
-409
-12% -$65.2K 0.17% 87
2025
Q1
$562K Buy
3,305
+186
+6% +$32.3K 0.24% 64
2024
Q4
$518K Hold
3,119
0.22% 69
2024
Q3
$536K Sell
3,119
-388
-11% -$64.2K 0.24% 61
2024
Q2
$540K Sell
3,507
-1,714
-33% -$257K 0.29% 54
2024
Q1
$803K Sell
5,221
-523
-9% -$79.7K 0.46% 43
2023
Q4
$908K Sell
5,744
-292
-5% -$41.9K 0.59% 37
2023
Q3
$883K Sell
6,036
-303
-5% -$46.2K 0.75% 31
2023
Q2
$971K Sell
6,339
-2,125
-25% -$331K 0.71% 36
2023
Q1
$1.31M Buy
8,464
+2,201
+35% +$346K 1.09% 25
2022
Q4
$965K Buy
+6,263
New +$924K 0.82% 39
2022
Q1
Sell
-1,504
Closed -$244K 179
2021
Q4
$244K Buy
+1,504
New +$243K 0.19% 139

Other funds holding FBT

WMG Financial Advisors's FBT Position: Q4 2025 in Review

WMG Financial Advisors sold out of First Trust NYSE Arca Biotechnology Index Fund (FBT) in Q4 2025, closing a stake of 2,720 shares — an estimated $488K sold.

WMG Financial Advisors first reported a position in FBT in Q4 2021 and held it in 13 quarters. The position peaked at $1.31M in Q1 2023. 279 funds tracked by Wall St. Rank hold FBT as of Q4 2025.

  • WMG Financial Advisors reported no remaining First Trust NYSE Arca Biotechnology Index Fund position as of Q4 2025 after selling out during the quarter.
  • WMG Financial Advisors sold 2,720 First Trust NYSE Arca Biotechnology Index Fund shares in Q4 2025, an estimated $488K.
  • WMG Financial Advisors first reported a position in First Trust NYSE Arca Biotechnology Index Fund in Q4 2021 and held it in 13 quarters.
  • WMG Financial Advisors's First Trust NYSE Arca Biotechnology Index Fund position peaked at $1.31M in Q1 2023.
  • 279 funds tracked by Wall St. Rank held First Trust NYSE Arca Biotechnology Index Fund as of Q4 2025.

Based on WMG Financial Advisors's 13F filing for Q4 2025, filed 28 Jan 2026.